Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Persistence-dependent effectiveness of tirzepatide on the cardio-metabolic-kidney syndrome outcomes in obesity : real-world evidence from the United Arab Emirates
Authors:ID Rangraze, Imran (Author)
ID El-Tanani, Mohamed (Author)
ID Janež, Andrej (Author)
ID Maggio, Viviana (Author)
ID Rabbani, Syed Arman (Author)
ID Jensterle Sever, Mojca (Author)
ID Munda, Ana (Author)
ID Abbas, Elhadi Eltayeb (Author)
ID Ali, Humam Sami (Author)
ID Farooqi, Mohammad Rashid (Author)
ID Patni, Mohamed Anas Faruk (Author)
ID Rizzo, Manfredi (Author)
Files:.pdf PDF - Presentation file, download (410,42 KB)
MD5: 98A5859529316B24F9A5F49487C9FC25
 
URL URL - Source URL, visit https://link.springer.com/article/10.1007/s13300-026-01868-2
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:Introduction: Tirzepatide has been associated with significant reductions in body weight in randomized clinical trials. However, real-world evidence evaluating the multisystemic effects of tirzepatide across the cardio-metabolic-kidney (CKM) continuum remains limited. The aim of this study was to assess the real-world persistence-driven cumulative benefits of tirzepatide beyond weight reduction in adults with obesity but without type 2 diabetes mellitus (T2DM). Methods: This single-center observational cohort study evaluated in the United Arab Emirates adults with obesity (body mass index [BMI] ≥ 30 kg/m2) treated with tirzepatide. Participants were stratified by treatment persistence: ≤ 1 year (short-term) and > 1 year (long-term). Anthropometric, glycemic, lipid, hepatic, and renal outcomes were assessed at baseline and follow-up. Results: One hundred participants (25 women; mean age 37.6 ± 10.0 years; baseline BMI 35.0 [33.0-39.0] kg/m2) were included. Median weight reduction was - 8.1% in the short-term group and - 22.6% in the long-term group (p < 0.001). 62% of long-term treated individuals achieved > 15% weight loss versus 20% among short-term users. Significant between-group differences were observed in BMI (- 8.3% vs. - 19.1%), waist circumference (- 4.0% vs. - 9.2%), and glycated hemoglobin (HbA1c) (- 5.0% vs. - 7.2%). Total cholesterol decreased by - 10.1% vs. - 18.7% (p = 0.005), low-density lipoprotein cholesterol (LDL-C) by - 9.6% vs. - 30.5% (p < 0.001), and triglycerides by - 11.2% vs. - 32.5% (p < 0.001). Liver enzymes, aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) declined by - 11.3% and - 13.2%, respectively, in long term group with no significant improvement in short term group (between-groups p values for both liver enzymes < 0.05). Serum creatinine declined significantly in the long-term group (- 6.6%, p < 0.001), estimated glomerular filtration rate (eGFR) increasing by + 3.2% (p = 0.001), and blood urea nitrogen (BUN) decreasing by - 7.8% (p = 0.006) while microalbuminuria showed no meaningful changes. Weight loss correlated with improvements in LDL-C, triglycerides, and SGOT, and inversely with high-density lipoprotein cholesterol (HDL-C) changes. Conclusions: Tirzepatide showed greater cumulative benefits across CKM syndrome outcomes during the second treatment year, highlighting the need to overcome adherence barriers in real-world settings.
Keywords:cardio-metabolic-kidney syndrome, obesity, tirzepatide, treatment, real-world evidence
Publication status:Published
Publication version:Version of Record
Year of publishing:2026
Number of pages:str. 873–884
Numbering:Vol. 17, issue 6
PID:20.500.12556/DiRROS-31850 New window
UDC:616.4
ISSN on article:1869-6961
DOI:10.1007/s13300-026-01868-2 New window
COBISS.SI-ID:276566275 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 25. 4. 2026;
Publication date in DiRROS:12.08.2026
Views:43
Downloads:21
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Diabetes therapy
Shortened title:Diabetes ther.
Publisher:Springer
ISSN:1869-6961
COBISS.SI-ID:520452889 New window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.

Secondary language

Language:Slovenian
Keywords:kardiometabolni ledvični sindrom, debelost, tirzepatid


Back